<DOC>
<DOCNO>1050921_business_story_5264329.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Matrix acquires Swiss firm

 OUR SPECIAL CORRESPONDENT 

 Mumbai, Sept. 20: Hyderabad-based Matrix Laboratories is acquiring a 43 per cent stake in Switzerland-based technology platform company Explora Laboratories S.A for an undisclosed sum.

 According to Matrix, the acquisition of Explora would facilitate the development of anti-inflammatory cortico-steroids and anti-cancer drugs. 

 Explora is engaged in research and development of active pharmaceutical ingredients (APIs) and intermediates through chemical, biochemical and fermentation processes that goes into the manufacture of drugs.

 Matrix today informed the stock exchanges that Explora also has the know-how in the chemistry of nucleic acids mainly used in the development of anti-viral and anti-cancer drugs. 

 It also has a large portfolio of products in the therapeutic segments of central nervous system, cardiovascular, anti-bacterial, anti-viral, anti-retroviral, anti-asthma, anti-histamine, anti-fungal and pain management. 

 Matrixs acquisition of Explora will give the Indian company access to the Swiss firms scientific resources which, in turn, would accelerate the entry of Matrix into high growth potential and niche areas such as cortico-steroid and anti cancer segments. 

 In addition to development of niche generic APIs, Exploras technology platforms will also give Matrix the expertise in the area of contract research and manufacturing for the multinational branded pharmaceutical companies. 

 Explora is presently pursuing third party research works for a group of generic and branded pharmaceutical companies, including Matrix. 




</TEXT>
</DOC>